Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Neurosteroid enantiomer

Small molecule · developed by Oragenics

Phase 2 Most advanced trial
OGEN Developer
1 Registered trials

What is Neurosteroid enantiomer?

A non-natural synthetic neurosteroid enantiomer, described as a new chemical entity. It is being studied in mild traumatic brain injury and concussion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Oragenics, Inc. (OGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06870240 Phase 2 Mild Traumatic Brain Injury, Concussion Not yet recruiting OGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mild Traumatic Brain Injury, Concussion

More from Oragenics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGEN page.

Follow OGEN, the company behind Neurosteroid enantiomer

See OGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.